澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

AROVELLA THERAPEUTICS LTD

0.055

+0.0035.77%

成交量：81.16万

成交额：4.29万

市值：6,648.31万

市盈率：-9.48

高：0.057

开：0.052

低：0.051

收：0.052

52周最高：0.100

52周最低：0.046

股本：12.09亿

流通股本：8.96亿

量比：1.55

换手率：0.09%

股息：- -

股息率：- -

每股收益(TTM):-0.006

每股收益(LYR):-0.006

净资产收益率：-40.41%

总资产收益率：-26.35%

市净率：4.70

市盈率(LYR):-9.48

数据加载中...

总览公司新闻资讯公告

查尔斯河实验室将开展Ala-101临床批次病毒安全性放行检测

查尔斯河为Arovella Therapeutics提供NGS服务，加速推进替代性癌症疗法研发

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/ALA.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.055,"timestamp":1791781920000,"preClose":0.052,"halted":0,"volume":811621,"delay":0,"changeRate":0.057692307692307744,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":895858885,"shares":1208783672,"eps":-0.0058,"marketStatus":"未开盘","change":0.003,"latestTime":"10-12 16:12:00 AEDT","open":0.052,"high":0.057,"low":0.051,"amount":42852,"amplitude":0.115385,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0058,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.052,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":1.5524282936236284,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ALA.AU","preClose":0.052,"auctionPrice":0.055,"auctionVolume":13817,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781792361}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":895858885,"roa":"-26.35%","roe":"-40.41%","lyrEps":-0.0058,"volumeRatio":1.5524282936236284,"shares":1208783672,"dividePrice":0,"high":0.057,"amplitude":0.115385,"preClose":0.052,"low":0.051,"week52Low":0.046,"pbRate":"4.70","psRate":"19.01","week52High":0.1,"institutionHeld":0,"latestPrice":0.055,"eps":-0.0058,"divideRate":0,"volume":811621,"delay":0,"ttmEps":-0.0058,"open":0.052,"prevYearClose":0.093,"prevWeekClose":0.052,"prevMonthClose":0.048,"prevQuarterClose":0.048,"fiveDayClose":0.048,"twentyDayClose":0.06,"sixtyDayClose":0.065},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1187663913","title":"查尔斯河实验室将开展Ala-101临床批次病毒安全性放行检测","url":"https://stock-news.laohu8.com/highlight/detail?id=1187663913","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187663913?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 20:06","pubTimestamp":1783944395,"startTime":"0","endTime":"0","summary":"查尔斯河实验室国际公司宣布，将为Ala-101的临床批次进行病毒安全性放行测试。这项关键检测旨在确保生物制剂在临床应用前的安全性与合规性，标志着该候选药物向临床开发阶段迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ALA.AU","LU0390134368.USD","BK4530","LU0757428866.USD","BK7096","CRL","LU0029874061.USD","BK4585","IE00BFMHRM44.USD","LU1815336091.USD","BK4121","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169951164","title":"查尔斯河为Arovella Therapeutics提供NGS服务，加速推进替代性癌症疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1169951164","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169951164?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 20:04","pubTimestamp":1783944261,"startTime":"0","endTime":"0","summary":"查尔斯河实验室已向Arovella Therapeutics Ltd提供下一代测序服务，此举旨在加速开发创新的替代性癌症治疗方法。这项合作将利用查尔斯河在NGS技术方面的专业能力，支持Arovella Therapeutics推进其肿瘤治疗研发管线。通过提供关键的基因组学数据和分析服务，查尔斯河将帮助Arovella更深入地理解疾病机制，并加速潜在疗法的发现与优化进程。此次服务合作凸显了生物技术公司与专业研发服务提供商之间协同的重要性，共同致力于应对癌症治疗领域的复杂挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRL","LU0757428866.USD","BK4585","IE00BFMHRM44.USD","BK4530","LU1815336091.USD","BK7096","LU0029874061.USD","LU0128526141.USD","BK4588","LU0390134368.USD","ALA.AU","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}